Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nedosiran in Primary Hyperoxaluria Type 1 with severe renal impairment
NCT04580420Phase 2Recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2021
- Primary completion
- Dec 2031
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 10
01
Overview
A Phase 2 trial of nedosiran in Primary Hyperoxaluria Type 1 (PH1), sponsored by Novo Nordisk. Started Apr 2021; status: recruiting.
02
Drugs
nedosiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NCT04580420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580420.